Baxdela 450 mg/1
delafloxacin meglumine · TABLET · Melinta Therapeutics, LLC
Baxdela is a tablet containing delafloxacin meglumine at 450 mg/1, taken oral. Manufactured by Melinta Therapeutics, LLC.
Key Facts
- Brand Name
- Baxdela
- Generic Name
- delafloxacin meglumine
- NDC Code (Product)
70842-101- Manufacturer
- Melinta Therapeutics, LLC
- Strength
- 450 mg/1
- Dosage Form
- TABLET
- Route
- ORAL
- Marketing Status
- Application #
- NDA208610
- Marketing Start
- 06/19/2017
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Frequently Asked Questions
What is Baxdela used for?
Baxdela contains delafloxacin meglumine. It is a tablet taken oral. Consult your doctor for specific uses.
Is Baxdela a controlled substance?
Baxdela is not classified as a controlled substance by the DEA.
What is the generic name for Baxdela?
The generic name for Baxdela is delafloxacin meglumine. There are no other listed brand versions of delafloxacin meglumine.
What is the NDC code for Baxdela 450 mg/1?
The NDC (National Drug Code) for Baxdela 450 mg/1 is 70842-101, listed by Melinta Therapeutics, LLC.
Other Baxdela Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)